Positive 25 Sep, 10:31 Impact +5

Nanexa shares rise 120% on $1.3bn Novo Nordisk obesity-drug partnership

Negative 21 Sep, 12:00 Impact -7

Novo Nordisk Shares Drop 7% Following Capital Markets Day Announcement

Positive 16 Sep, 21:30 Impact +5

Novo Nordisk Shares Rise Following US Approval of Weight Loss Pills

Positive 16 Sep, 21:30 Impact +5

Novo Nordisk Receives U.S. Approval for Wegovy Obesity Tablets

Negative 16 Sep, 21:30 Impact +5

Novo Nordisk Halves Wegovy Prices in Select Chinese Provinces

Positive 16 Sep, 21:30 Impact +5

Amazon Pharmacy Now Offers Novo Nordisk's Wegovy with Insurance and Payment Plans

Product 16 Sep, 21:30 Impact +5

UBS Raises Novo Nordisk Price Target to 390 DKK Ahead of Wegovy Launch

Positive 16 Sep, 21:30 Impact +5

MHRA Approves Higher Dose of Wegovy for Obesity Treatment by Novo Nordisk

Positive 16 Sep, 21:30 Impact +5

Novo Nordisk Shares Rise 9% Following Strong Sales Launch of GLP-1 Obesity Drug

Negative 16 Sep, 21:30 Impact +5

Novo Nordisk Issues Downbeat Forecast with 18% Decline

Negative 16 Sep, 21:30 Impact +5

Novo Nordisk Faces Pricing Pressure on Wegovy Amid Leadership Changes

Positive 16 Sep, 21:30 Impact +5

Hims Discontinues Obesity Pill, Potentially Benefiting Novo Nordisk

Product 16 Sep, 21:30 Impact +5

Novo Nordisk Initiates DKK 15 Billion Share Buyback Program

Negative 16 Sep, 21:30 Impact +5

Novo Nordisk Weight Loss Drug Underperforms Compared to Eli Lilly's Product in Trials

Negative 16 Sep, 21:30 Impact +5

Novo Nordisk to Reduce Diabetes and Obesity Drug Prices in the U.S. by 2027

Product 16 Sep, 21:30 Impact +5

Novo Nordisk Launches Subscription Program for Wegovy to Compete with Eli Lilly

Positive 16 Sep, 21:30 Impact +5

Novo Nordisk predicts sales growth thanks to new obesity pill Wegovy

Positive 16 Sep, 21:30 Impact +5

Novo Nordisk 's obesity drug Wegovy has been recommended for approval in Europe.

Product 16 Sep, 21:30 Impact +5

Novo Nordisk Launches Ozempic Sales in India

Positive 16 Sep, 21:30 Impact +5

Novo Nordisk to Cut 9,000 Jobs as Part of Restructuring Efforts

Neutral 16 Sep, 21:30 Impact +5

Novo Nordisk Acquires Akero Therapeutics for $5.2 Billion

Negative 16 Sep, 21:30 Impact +5

Novo Nordisk Faces Pressure as Trump Promises Lower Weight Loss Drug Prices

Negative 16 Sep, 21:30 Impact +5

Pfizer Sues Metsera and Novo Nordisk Over Competing Obesity Drug Offerings

Positive 16 Sep, 21:30 Impact +5

Novo Nordisk Plans Acquisition of Metsera for $6.5 Billion

Negative 16 Sep, 21:30 Impact +5

Novo Nordisk Reports Results Within Expectations, Lowers Forecasts

Negative 16 Sep, 21:30 Impact +5

Novo Nordisk Continues to Lose Market Share in Obesity Drug Sector

M&A 16 Sep, 21:30 Impact +5

Novo Nordisk Shares Rise Following Exit from Metsera Acquisition Bid

Negative 16 Sep, 21:30 Impact +5

Novo Nordisk Reduces Wegovy Prices in India by 37%

Negative 16 Sep, 21:30 Impact +5

Novo Nordisk Reduces Prices for Wegovy and Ozempic to $349 per Month

Negative 16 Sep, 21:30 Impact +5

Novo Nordisk Reports Unsuccessful Alzheimer Drug Trial Results

Negative 16 Sep, 21:30 Impact +5

Novo Nordisk Shares Drop 12.4% Following Ozempic Alzheimer's Study Results

Negative 16 Sep, 21:30 Impact +5

Novo Nordisk Loses Four Years of Growth Amid Rising Competition in Obesity Treatments

Neutral 7 Aug, 11:07 Impact +5

Porsche Reports 14.5% Decline in Q1 2026 Profit, Calls for Reforms at Volkswagen

Neutral 29 Jul, 08:43 Impact +5

Porsche Reports Q1 2026 Operating Profit of €1.35 Billion, Exceeding Expectations

Neutral 27 Jul, 15:39 Impact +5

Porsche Plans to Cut 5,000 Jobs by 2035 as Part of Restructuring Efforts